Ad
CGO - Calamos Global Total Return Fund Stock Trading
About | Calamos Global Total Return Fund (NASDAQ:CGO)
Not available
Quote | Calamos Global Total Return Fund (NASDAQ:CGO)
| Last: | $8.7299 |
|---|---|
| Change Percent: | 0.24% |
| Open: | $8.73 |
| Close: | $8.7299 |
| High: | $8.7488 |
| Low: | $8.6998 |
| Volume: | 14,658 |
| Last Trade Date Time: | 10/02/2023 03:00:00 am |
News | Calamos Global Total Return Fund (NASDAQ:CGO)
-
2023-08-22 01:23:37 ET Summary Perfection is defined as being complete and correct in every way, and can be pursued in various fields, including art and investing. For years now, I have been employing all my strength in investing in CEFs and ETFs, plus some “flirtations...
-
Cogeco Releases its Financial Results for the Third Quarter of Fiscal 2023 Canada NewsWire In the context of its network expansion strategy, Cogeco added 30,922 homes passed in Canada and the United States , totalling 101,000 homes passed over the past nine months; ...
Message Board Posts | Calamos Global Total Return Fund (NASDAQ:CGO)
| Subject | By | Source | When |
|---|---|---|---|
| Stock_Tracker: Latest Calamos Global Total Return Fund (CGO) Headlines Ameren Warns of Nationwide Em | Stock_Tracker | investorshangout | 03/14/2014 1:50:16 AM |
| chartguy89: CGO Stock Charts Last: -0.19 Monday, March 3, 2014 at 7:54:42 PM $CGO 1 Month Ch | chartguy89 | investorshangout | 03/04/2014 12:54:53 AM |
Calamos Global Total Return Fund Company Name:
CGO Stock Symbol:
NASDAQ Market:
Ad
-
Cogeco Releases its Financial Results for the Third Quarter of Fiscal 2023 Canada NewsWire In the context of its network expansion strategy, Cogeco added 30,922 homes passed in Canada and the United States , totalling 101,000 homes passed over the past nine months; ...
-
Cogeco Releases its Financial Results for the Second Quarter of Fiscal 2023 Canada NewsWire Revenue increased by 1.2% (decrease of 1.6% in constant currency (1) ) compared to the same period of the prior year to $757.2 million ; Adjusted EBITDA (1) was ...
-
We are reaffirming our "buy" rating on Bio-Techne Corp. (TECH); we are encouraged by the company’s strong performance in fiscal 4Q21, notes David Toung, a healthcare sector analyst with Argus Research, a leading independent Wall Street research firm. For further details see: Bio-...